EchoIQ Ltd (ASX: EIQ) shares were on fire on Friday.
The ASX tech stock rocketed 30% to $1.62 after Pro Medicus Ltd (ASX: PME) announced a major investment in the company and a marketing agreement.
The market appears to see this investment as a stamp of approval from the medical imaging technology provider.
Pro Medicus’ CEO, Dr Sam Hupert, commented:
In addition to providing financial backing, we are looking to offer our Visage 7 Cardiology customers the option of Echo IQ’s technology. This is in line with our AI strategy of offering a curated suite of algorithms that will be a mixture of algorithms created by us, those created in conjunction with our clinical partners and 3rd party algorithms such as Echo-IQ.
Is it too late to buy this ASX tech stock?
The good news is that Bell Potter doesn’t believe it is too late to buy this high-flying share. However, the near-term upside from here could be limited.
According to a note, the broker has initiated coverage on the cardiology-focused medical technology company’s shares with a speculative buy rating and $1.65 price target. This is just a fraction higher than where its shares currently trade.
Bell Potter believes there is a major unmet need that the ASX tech stock could help with. It explains:
The major unmet need in this patient population are those currently asymptomatic (i.e. without obvious symptoms) with severe disease. The vast majority proceed to symptomatic disease within two years and become candidates for aortic value replacement. Recent clinical data has proven that early intervention drives a significant survival benefit.
The data suggest that the majority of these patients are not identified using current screening methods and fewer still receive treatment. Finally, this recent clinical data has been recognised by CMS which recently proposed an update to its National Coverage Determination to extend reimbursement for AS patients with asymptomatic disease.
Commenting on its speculative buy rating, Bell Potter adds:
We commence coverage with a Buy (Speculative) recommendation and valuation of $1.65. We expect EIQ expand rapidly over the short to medium term as healthcare operators and payers recognise the benefit of these diagnostic aides in helping to minimise the long term cost of heart failure to US healthcare.
Overall, this could make it one to watch in the near term.
The post Is this exciting ASX tech stock a buy after its massive news? appeared first on The Motley Fool Australia.
Should you invest $1,000 in Echo IQ Ltd right now?
Before you buy Echo IQ Ltd shares, consider this:
Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Echo IQ Ltd wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
And right now, Scott thinks there are 5 stocks that may be better buys…
* Returns as of 16 June 2026
.custom-cta-button p {
margin-bottom: 0 !important;
}
More reading
- Pro Medicus just struck a revolutionary AI cardiology deal. Here’s why that matters
- Why is everyone talking about Mineral Resources, A2 Milk and Pro Medicus shares on Thursday?
- Why A2 Milk, EchoIQ, Lendlease, and Qantas shares are racing higher today
- A deal with Pro Medicus has turned this ASX biotech into a 10-bagger, up more than 30% today
- Pro Medicus shares jump again as AI deal adds fuel to 40% rally
Motley Fool contributor James Mickleboro has positions in Pro Medicus. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.